Exagen Inc. to Participate in the William Blair 43rd Annual Growth Stock Conference
May 30, 2023 09:00 ET
|
Exagen Inc.
SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the William Blair 43rd Annual Growth...
Digital PCR Market Share to Witness Stunning Growth at a CAGR of 15.3% by 2032: Market.us Analysis
May 30, 2023 08:08 ET
|
Market.Us
New York, May 30, 2023 (GLOBE NEWSWIRE) -- The Digital PCR Market Size accounted for USD 450 Million in 2022 and is estimated to garner a market size of USD 1,803 Million by 2032 rising at a CAGR of...
Mydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription Agreement and Provides Update on Its Board of Directors
May 29, 2023 19:42 ET
|
Mydecine Innovations Group Inc.
VANCOUVER, British Columbia, May 29, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the...
Monoclonal Antibodies Market Sales are Anticipated to reach US$ 588.0 Billion by 2032, Increasing at 11.8% CAGR: Market.us Report
May 26, 2023 01:50 ET
|
Market.Us
New York, May 26, 2023 (GLOBE NEWSWIRE) -- The Monoclonal Antibodies Market size was valued at USD 198.2 Bn in 2022. The total market revenue is expected to grow at a CAGR of 11.8%, reaching...
KAIST and Checkmate Capital Complete Investment in Bredis Healthcare
May 25, 2023 18:00 ET
|
Checkmate Capital
Investment Accelerates Bredis’ Capacity Expansion, Integrated Platform Development and Commercialization in Korea Further Announcement of Bredis’ Agreements with Major University Hospitals SEOUL,...
PDS Biotech Announces Interim Data Demonstrates 12-Month Survival Rate of 87% with PDS0101 in Combination with KEYTRUDA® (pembrolizumab) for Head and Neck Cancer Patients
May 25, 2023 17:00 ET
|
PDS Biotechnology Corporation
Interim data being presented at ASCO 2023 Annual Meeting Demonstrated median progression-free survival (PFS) of 10.4 months Demonstrated 12-month overall survival (OS) rate of 87.1%A disease control...
Kane Biotech Announces First Quarter 2023 Financial Results
May 25, 2023 16:05 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, May 25, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and...
Kane Biotech Announces FDA 510(k) Clearance for its coactiv+™ Antimicrobial Wound Gel
May 25, 2023 10:38 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, May 25, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces that on May 24, 2023 it received 510(k) clearance of its...
Stereotaxis to Participate in 20th Annual Craig-Hallum Institutional Investor Conference
May 25, 2023 08:56 ET
|
Stereotaxis, Inc.
ST. LOUIS, May 25, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David...
Lumos Pharma Announces Abstracts Accepted for Oral Presentation at 2023 ENDO Meeting with Virtual KOL Event to be Held on June 21st
May 25, 2023 08:00 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, May 25, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for idiopathic Pediatric Growth Hormone...